Intracranial Aneurysm Market - Strategic Insights and Forecasts (2026-2031)

The intracranial aneurysm market is forecast to grow at a CAGR of 8.8%, reaching USD 2.9 billion in 2031 from USD 1.9 billion in 2026.

Market Overview

Intracranial aneurysms are focal dilations of cerebral arteries that can remain asymptomatic for years or rupture and cause aneurysmal subarachnoid hemorrhage. A 2025 systematic review and meta-analysis covering 304,848 subjects estimated overall unruptured intracranial aneurysm prevalence at 5.4%, while the long-established pooled benchmark for populations without major comorbidity is approximately 3.2%. Advancing age, female sex, hypertension and smoking were identified as important predictors, creating a substantial underlying population from which higher-risk patients may progress to surveillance or preventive treatment.

The market boundary is better defined around aneurysm treatment devices and procedure-specific consumables rather than general CT or MRI capital equipment. CTA, MRA and catheter angiography are essential to diagnosis and treatment planning, but the economics of a CT scanner or MRI system cannot reasonably be attributed solely to intracranial aneurysm treatment. Diagnostic modalities are therefore analyzed as clinical-pathway enablers rather than revenue segments. Commercial revenue is concentrated in embolization coils, flow diverters, intrasaccular flow-disruption devices, clipping systems, and related neurovascular delivery products.

Clinical management is increasingly concentrated in experienced neurovascular centers. The American Heart Association and American Stroke Association recommend prompt identification and treatment of ruptured aneurysms, preferably within 24 hours, and emphasize transfer to centers with multidisciplinary neurocritical-care and aneurysm-treatment expertise. This supports high-value device utilization in hospitals while limiting access in regions without established stroke and neurointerventional infrastructure.

Market Trends

• Intrasaccular Flow Disruption Is Expanding Treatment Options

Intrasaccular devices treat an aneurysm from within the sac rather than reconstructing the parent vessel using a conventional flow-diverting stent. Terumo Neuro launched the WEB 17 Aneurysm Embolization System in Japan in May 2026, following regulatory approval in November 2025, for ruptured and unruptured intracranial aneurysms. In August 2026, the company also reported separate one-year WISE study publications covering ruptured and unruptured WEB-treated cohorts. The technology is particularly relevant to wide-neck bifurcation aneurysms where conventional coiling may require additional stents or balloons.

• Flow Diverters Are Moving Toward Improved Surface and Delivery Technologies

Flow diversion remains one of the most important innovation areas for complex and wide-neck aneurysms. Medtronic reports that more than 100,000 patients have been treated using its Shield Technology, while newer Pipeline generations broaden catheter and size options. Stryker is advancing the Surpass Elite platform, with a 2026 publication describing first clinical experience across 81 treated aneurysms. WallabyPhenox began U.S. enrollment in the PIANO IDE trial for its p48 and p64 MW HPC devices in March 2026. Competition increasingly centers on deliverability, wall apposition, surface modification, and thromboembolic performance alongside aneurysm occlusion.

• Intravascular Imaging Is Emerging as a Procedural Adjunct

Aneurysm treatment is beginning to incorporate more detailed intravascular imaging. Spryte Medical completed enrollment in the INSYTE trial in July 2026 for its neuro-optical coherence tomography system, an FDA-approved IDE study evaluating high-resolution intravascular imaging during aneurysm treatment and follow-up. The technology remains an emerging adjunct rather than a large revenue segment, but it could improve assessment of implanted devices, vessel-wall interaction and treatment results if regulatory and reimbursement milestones are achieved.

Segment Analysis

• By Treatment Type: Endovascular Coiling

Endovascular coiling accounts for approximately 42% of global market value in 2026 and remains the largest treatment category. Coils are used across ruptured and unruptured aneurysms, while balloon-assisted and stent-assisted techniques extend their applicability to more complex anatomy. Product development remains active even as flow diversion and intrasaccular devices gain share. Terumo Neuro published results from the RAGE study in May 2026 covering second-generation HydroCoil embolization coils for ruptured intracranial aneurysms. Coiling is expected to lose some relative share through 2031 but remains central because of established clinical familiarity and broad procedural applicability.

• By Aneurysm Status: Unruptured Aneurysms

Unruptured aneurysms account for approximately 68% of market value in 2026. Improved CTA and MRA availability supports incidental detection, while treatment decisions increasingly incorporate aneurysm size, location, morphology, patient age, hypertension, smoking history and other rupture-risk factors. Not every identified aneurysm requires intervention, and surveillance remains appropriate for many lower-risk lesions. However, the large underlying prevalence creates a substantial population undergoing risk assessment and follow-up.

• By End-User: Hospitals

Hospitals account for approximately 91% of global market value in 2026 because intracranial aneurysm procedures require specialized neurovascular teams, advanced angiography, anesthesia, neurocritical care and immediate complication management. Comprehensive stroke centers and tertiary neurological hospitals therefore dominate device procurement. The AHA/ASA notes that experienced, higher-volume centers with dedicated neurocritical-care resources are associated with better outcomes in aneurysmal subarachnoid hemorrhage.

• By Geography: North America

North America accounts for approximately 41% of global market value in 2026, led by the United States. The region combines high access to neuroimaging and neurointerventional care with early adoption of flow diverters and intrasaccular technologies. The U.S. FDA maintains dedicated PMA pathways for intracranial aneurysm flow diverters and intrasaccular flow-disruption devices, creating a regulated but commercially important product environment.

Market Drivers

• Large Diagnosed and Undiagnosed Aneurysm Population

Intracranial aneurysms are considerably more common than treated-procedure volumes suggest. The traditional pooled prevalence estimate is approximately 3.2%, while the 2025 meta-analysis reported 5.4% across its included studies. Most aneurysms do not rupture and many never require treatment, but broader use of non-invasive brain imaging increases incidental identification and expands the population undergoing surveillance and rupture-risk assessment. Aging populations and the continuing prevalence of hypertension and smoking further support the long-term treatment pool.

• Endovascular Innovation Is Broadening Treatable Anatomy

Market expansion increasingly comes from the ability to treat lesions that previously had fewer suitable options. Coils remain broadly applicable, flow diverters reconstruct the parent vessel across the aneurysm neck, and intrasaccular devices offer another option for selected wide-neck bifurcation aneurysms. Lower-profile delivery systems also improve access to smaller and more distal vessels. The expansion of WEB in Japan, current Surpass Elite experience and the U.S. PIANO trial demonstrate a continuing widening of the treatment toolkit rather than convergence around one device category.

• Specialized Stroke Networks Support Advanced Device Adoption

Intracranial aneurysm care benefits from expanding comprehensive stroke centers and dedicated neurointerventional programs because complex procedures require multidisciplinary expertise. AHA/ASA guidance recommends rapid transfer of aneurysmal subarachnoid hemorrhage patients to experienced centers and prompt treatment of the ruptured aneurysm. As countries expand angiography capacity and neurointerventional training, a larger proportion of patients can access advanced treatment.

Market Restraints

• Treatment Decisions Must Balance Rupture Risk Against Procedural Risk

A large underlying prevalence does not translate directly into treatment volume. Many small or stable unruptured aneurysms are managed through surveillance because intervention itself carries risks including thromboembolism, hemorrhage, vessel injury, device complications and retreatment. Flow diversion can also require antiplatelet therapy, affecting patient selection and peri-procedural management. Market growth therefore depends on risk-based treatment rather than widespread screening followed automatically by intervention.

• Advanced Treatment Remains Concentrated in Specialized Centers

Access is constrained by the need for experienced operators, biplane angiography, neurocritical care and multidisciplinary surgical backup. These requirements create substantial regional differences in treatment rates. Device costs can also be significant when complex aneurysms require multiple coils, adjunctive stents, flow diverters or specialized delivery systems, limiting adoption outside high-volume tertiary hospitals.

Competitive Landscape

The intracranial aneurysm market is led by specialized neurovascular device manufacturers rather than hospitals or general diagnostic-imaging companies. Medtronic competes through the Pipeline flow-diverter family and Axium coils; Stryker through Surpass flow diversion and other neurovascular embolization products; Terumo Neuro/MicroVention through WEB, FRED and HydroCoil; and Johnson & Johnson MedTech/CERENOVUS through neurovascular treatment and access technologies. Penumbra, Balt, WallabyPhenox, MicroPort NeuroTech, Rapid Medical and Kaneka Medix broaden competition across coils, flow modulation, access and adjunctive systems.

The existing KSI company list therefore requires correction. Mayo Clinic, Johns Hopkins Medicine and Mayfield Clinic are important clinical institutions but are not commercial aneurysm-device manufacturers. Competitive advantage instead depends on clinical evidence, regulatory approval, physician training, catheter compatibility, deliverability, occlusion performance, complication profile and the breadth of complementary access products.

Recent Developments

• August 2026: Terumo Neuro announced one-year WISE publications for WEB treatment in separate ruptured and unruptured aneurysm cohorts.

• July 2026: Spryte Medical completed enrollment in the INSYTE IDE trial evaluating neuro-optical coherence tomography during aneurysm treatment and follow-up.

• May 2026: Terumo Neuro published North American RAGE study results for second-generation HydroCoil embolization coils in ruptured aneurysms.

• May 2026: Terumo Neuro launched the WovenEndoBridge™ 17 (WEB 17) Aneurysm Embolization System in Japan, expanding treatment options for ruptured and unruptured intracranial aneurysms.

• March 2026: WallabyPhenox announced the first U.S. patient treated in the PIANO IDE trial evaluating p48 and p64 MW HPC flow-modulation devices.

Market Outlook

The intracranial aneurysm market is expected to expand through 2031 as endovascular treatment becomes applicable to a broader range of aneurysm morphologies and more patients are identified through modern imaging. Coiling remains the largest treatment category in 2026, while flow diverters and intrasaccular devices gain share as clinical evidence and regulatory coverage expand. Hospitals remain the dominant end-user because treatment requires specialized neurovascular infrastructure, and North America retains the largest regional value pool.

Intracranial Aneurysm Market Scope: